Safety and daily life

Medicinal cannabis in New Zealand is not a general licence to use cannabis. It is a regulated pharmaceutical pathway under the Misuse of Drugs Act, and the only legal route to a product is a prescription from a medical practitioner. The Medicinal Cannabis Scheme, run by the Ministry of Health and administered by the Medicinal Cannabis Agency (MCA) within Medsafe, sets the rules for what can be prescribed, how products are manufactured, and how they reach you.

The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean you can legally smoke raw plant material bought from an unregulated source. The legal product is a manufactured pharmaceutical that meets GMP (Good Manufacturing Practice) standards and has been approved by the Ministry of Health. Even the raw flower, when it is prescribed, is dispensed through a pharmacy, not a dispensary or a friend’s stash. The Misuse of Drugs Act still applies to everything else.

This page is your map. It explains the legal pathway, the difference between the main product types, how to read a prescription, and how to fit medicinal cannabis into work, driving, parenting and daily routines. It then routes you to four focused guides for the detail. The practical safety advice here comes from New Zealand’s regulatory framework, Medsafe, and peer-reviewed clinical guidance published up to 2024-2025.

---

First: what the law actually allows

Since 1 April 2020, the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 has allowed a medical practitioner to prescribe cannabis-based products for any patient they consider may benefit, under the Medicinal Cannabis Scheme. The scheme is administered by the Medicinal Cannabis Agency (MCA), which sits inside Medsafe, the New Zealand medicines regulator. Products must be manufactured to Good Manufacturing Practice (GMP) standards and approved by the Ministry of Health before they can be prescribed and dispensed in New Zealand. (New Zealand Ministry of Health, Medicinal Cannabis Scheme, effective 1 April 2020.)

The key legal point: a prescription makes the product legal for that patient, but it does not legalise possession, use, or supply of cannabis outside the prescribed product. The Misuse of Drugs Act 1975 still applies. If a product is not a registered medicine under the scheme, it is not covered by a prescription. The scheme does not permit smoking raw plant material bought from unregulated sources, nor does it allow a patient to grow their own plants.

What counts as medicinal cannabis in New Zealand

Under the Medicinal Cannabis Scheme, a “medicinal cannabis product” is a pharmaceutical that meets GMP (Good Manufacturing Practice) standards and has been notified to the Ministry of Health (Medsafe, 2022). It is dispensed through a pharmacy, exactly like any other prescription medicine. The scheme is administered by the Medicinal Cannabis Agency, which sits within Medsafe. Products may be:

• Flower (dried plant material) for vaporisation, not for smoking
• Oils and oral solutions
• Capsules and tablets
• Isolates and powders (e.g., CBD isolate)
• Topical preparations

The Misuse of Drugs Act 1977 remains the legal backbone; the scheme operates under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. Under these regulations, a medical practitioner can prescribe a medicinal cannabis product that meets GMP standards and is approved by the Ministry of Health. The patient must have a prescription; there is no “general licence” to use cannabis for any reason. The Misuse of Drugs Act still lists cannabis as a controlled drug, and possession without a prescription remains illegal.

PRODUCTS: - Flower: dried cannabis flower, vaporised or inhaled; onset 5-10 min, duration 2-4 hours; THC content ranges from <1% to 25%; CBD content ranges from <1% to 12%; examples: Tilray 10:10, Medleaf THC25, Aurora Sedaprem, Spectrum Red No. 1, LGP Classic 10:10, Bedrocan, Eve. - Oils: sublingual or oral; onset 30-90 min, duration 6-8 hours; THC or CBD dominant, or balanced; examples: Tilray 10:10 oil, Medleaf THC10:CBD10, Cann Group CBD100, Helius THC25, NUBU 100. - Capsules: oral, slow onset; examples: Cann Group THC20 capsules, Tilray capsules (if available). - Isolate powder: pure CBD or THC in powder form; example: Cannabisol 100 (CBD isolate). - Topicals: creams and balms; limited evidence for localised pain; not psychoactive. - Vape cartridges: available in NZ but less common; require a prescription and are not funded.

VERIFIED RESEARCH FOR SAFETY AND DAILY LIFE PAGE: - In New Zealand, medicinal cannabis products must be approved by the Ministry of Health and meet GMP standards under the Medicinal Cannabis Scheme (Ministry of Health, 2020). - Access requires a prescription from a medical practitioner registered with the Medical Council of New Zealand (Ministry of Health, 2020). - Under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, the raw cannabis plant may be prescribed, but it must be supplied through a licensed pharmacy, not a dispensary (Ministry of Health, 2020). - The Medicinal Cannabis Agency (MCA), part of Medsafe, issues licences and oversees the scheme (Ministry of Health, 2020). - Products must meet GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health before they can be prescribed (Medsafe, 2021). - THC is the main psychoactive compound; CBD is non-psychoactive; both are measured in mg/g on labels (Medsafe, 2022). - Inhaled flower has an onset of 5-10 minutes and duration of 2-4 hours; oral oils have an onset of 60-120 minutes and duration of 6-8 hours (NZ Formulary, 2021). - Bioavailability: inhaled THC ~25-30%; oral oils ~10-20% due to first-pass metabolism (NZ Formulary, 2021). - Common adverse effects include drowsiness, dizziness, dry mouth, increased appetite, and transient anxiety; serious risks include psychosis, particularly in young people and those with a history of psychiatric disorder (NZ Formulary, 2021). - In New Zealand, a prescription is the only legal route; products must be GMP-certified and approved by the Ministry of Health under the Medicinal Cannabis Scheme. The Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 govern access. - The Medicinal Cannabis Scheme was fully operational from 1 April 2020, with the first products listed by mid-2020 (Ministry of Health, 2020). - The scheme sets maximum limits: dried flower must be ≤ 25% THC and ≤ 0.2% CBD; oils must be ≤ 50 mg/mL THC; and products must meet GMP standards. - The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (effective 1 April 2020) set the framework. - Under the scheme, a prescription from a medical practitioner is required; pharmacists must verify the prescription and dispense the product. Only a medical practitioner can prescribe, not a nurse practitioner or pharmacist. - The Ministry of Health’s Medicinal Cannabis Agency (MCA) is the regulator, and Medsafe is the medicines regulator. - Medicinal cannabis products in New Zealand are either “CBD-only” (CBD as the sole active ingredient) or “THC-containing” (THC alone or in combination with CBD). - CBD-only products are not controlled drugs under the Misuse of Drugs Act and can be prescribed by any doctor. - THC-containing products are controlled drugs, but any doctor can prescribe them under the scheme; no special authorisation is needed. - New Zealand doctors do not need a special licence to prescribe medicinal cannabis, but they must follow the Misuse of Drugs Regulations 1977 and the Medicinal Cannabis Scheme. - The Medicinal Cannabis Scheme began 1 November 2020, administered by the Medicinal Cannabis Agency (MCA), which is part of Medsafe. - Under the scheme, products must meet GMP standards, be manufactured to pharmaceutical quality, and be approved by the Ministry of Health. The scheme was created by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, and its regulations took effect on 1 April 2020. - The raw flower (dried bud) is a legal prescription product in New Zealand, but it is dispensed through a pharmacy, not a coffee shop or dispensary, and it is not a licence to smoke raw plant material in public. - The scheme does not allow a person to grow their own cannabis, buy from an unlicensed source, or possess cannabis without a prescription. The Ministry of Health states that possession without a prescription remains an offence under the Misuse of Drugs Act 1975. - The Ministry of Health’s Medicinal Cannabis Agency (MCA) runs the scheme. The MCA licences cultivators, manufacturers and pharmacies. It also maintains a public register of notified products. - In 2024 the Medicinal Cannabis Agency reported 6,000 product notifications; by 2025 the number was over 7,000. - The most common medical conditions for which medicinal cannabis is prescribed in New Zealand are chronic pain, cancer-related symptoms, and refractory epilepsy. - The regulatory threshold: a product must contain no more than 2% of specified controlled drugs (e.g., THC) by weight in the final product to be considered a “CBD-dominant” product. Products above this threshold are “THC-dominant” and have stricter controls. - The New Zealand Medicinal Cannabis Scheme (under the Misuse of Drugs Act 1975) requires that all products meet GMP standards and are approved by the Ministry of Health. The scheme is administered by the Medicinal Cannabis Agency (MCA), a business unit of Medsafe. - In New Zealand, medicinal cannabis is a prescription medicine, not an over-the-counter product. A doctor must assess the patient and issue a prescription; pharmacists dispense the product. The scheme does not permit general access, and possession without a prescription is illegal under the Misuse of Drugs Act 1975. - “Prescription” in this context means a legal authorisation from a medical practitioner, typically a specialist or GP with prescribing rights, under the Misuse of Drugs Act. The prescription must be for a specific product, dose, and administration route. Pharmacists dispense it like any other controlled medicine. - “Medsafe” is the New Zealand Medicines and Medical Devices Safety Authority, part of the Ministry of Health. It assesses the quality, safety and efficacy of medicines, and in the cannabis scheme it approves each product and sets GMP and testing standards. - “New Zealand’s Medicinal Cannabis Scheme” was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and fully operational from 1 April 2020. It creates a regulated pathway for patients to access quality-assured medicinal cannabis products. - “Medicinal cannabis in New Zealand” means a prescription medicine supplied through a pharmacy, not a general licence to use cannabis. The scheme is governed by the Misuse of Drugs Act and administered by the Medicinal Cannabis Agency (MCA) within Medsafe. - “The patient pathway” is: see a doctor, get a prescription, take it to a pharmacy, and the pharmacist dispenses a GMP-certified product. The doctor must consider the NZ Formulary guidance and can prescribe products not on the Formulary if they take responsibility. No product can be legally accessed without a prescription. - “Understanding the evidence”: The evidence base for medicinal cannabis is mixed. For chronic pain, the strongest evidence is for neuropathic pain, but effect sizes are modest and adverse effects are common. For spasticity in multiple sclerosis, a 2021 systematic review found moderate-quality evidence for symptom relief. For epilepsy, Epidyolex (pure CBD) is the only product with robust evidence in Dravet and Lennox-Gastaut syndromes. For anxiety, depression, PTSD, and insomnia, evidence is largely preliminary or mixed; no high-quality trials support routine use. For cancer-related symptoms, evidence is limited for pain and nausea, with significant uncertainty. For palliative care, the evidence is mixed but some patients report improved appetite and sleep. The scheme does not approve cannabis for recreational use or for “general wellness” without a clinical indication. - CBD: In New Zealand, CBD is a prescription medicine, not an over-the-counter supplement. It is legal to possess and use only with a valid prescription under the Misuse of Drugs Act. CBD is non-psychoactive, but it is not a licensed medicine for all conditions; the evidence is strongest for certain types of epilepsy (e.g., Dravet and Lennox-Gastaut syndromes) and for anxiety, but the NZ Formulary notes that evidence for other conditions is mixed. Patients should not self-medicate with unregulated CBD oil bought online; these products are illegal and may contain contaminants. - THC: THC is the main psychoactive compound in cannabis and is controlled under the Misuse of Drugs Act. It is available by prescription in New Zealand as a manufactured pharmaceutical, not as raw plant material for smoking. THC is the main driver of both therapeutic effects (pain, appetite, nausea) and adverse effects (sedation, cognitive impairment, psychosis risk in susceptible people). The NZ Formulary advises starting low and titrating slowly under medical supervision. - Medsafe: Medsafe is New Zealand’s medicines regulator. It approves individual medicinal cannabis products and enforces GMP, and the Medicinal Cannabis Agency (MCA) sits within it and issues licences to import, manufacture and supply. Medsafe’s role is product quality and safety, not clinical advice; prescribers use the NZ Formulary for dosing guidance. - Prescription: In New Zealand, medicinal cannabis is a prescription medicine under the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. A doctor can prescribe it for any condition they believe it may help, but in practice most prescriptions are for chronic pain, cancer-related symptoms, or refractory epilepsy. The prescription is the only legal gateway; without it, possession or use is an offence under the Misuse of Drugs Act 1975. For most patients, the pathway starts with a GP or specialist, and the prescription is dispensed by a New Zealand pharmacy.